A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
This research study is looking into a new medicine called Zilucoplan for young people diagnosed with generalised myasthenia gravis, a condition that causes muscle weakness. The main goal is to find out more about how Zilucoplan behaves in the body of children and teenagers, including how much of it reaches different parts of the body and how long it stays there. We also want to see if the medicine is safe and if it causes any unwanted side effects. Importantly, the study will also help us understand if Zilucoplan can improve the symptoms of gMG in young patients. This information is key to deciding if this new treatment could be a good option for future care.
En un coup d'œil
De quoi parle cette étude ?
This study is about a new medicine called Zilucoplan, and it's for young people who have a condition called generalised myasthenia gravis, or gMG. Myasthenia gravis is a long-term condition that causes muscles to become weak and tired easily. This can affect things like how you move your eyes, swallow, speak, or even move your arms and legs. We don't have many treatment options specifically for children and teenagers with gMG, so finding new ones is really important.
In this study, doctors want to learn more about how Zilucoplan works in the bodies of young people. They will be looking at things like how quickly the medicine gets into the body, how it affects certain body processes, and if it's generally safe for children and teenagers to use. They'll also be carefully checking for any side effects and seeing if the medicine helps improve the muscle weakness that comes with gMG. The study is currently in Phase 2 and 3, which means it has already been tested in some people and is now being studied more widely to see how well it works compared to existing treatments, if any, and its overall safety.
The information gathered from this study will help us understand if Zilucoplan could be a helpful new treatment option for young people with gMG in the future. Finding effective and safe treatments is crucial for improving the quality of life for those living with this condition.
Points clés
- Tests a new medicine, Zilucoplan, for young people with gMG.
- Aimed at improving muscle weakness and overall health.
- Involves regular check-ups, blood tests, and symptom tracking.
- Free to participate and can withdraw at any time.
- Helps scientists learn more about gMG treatments for the future.
Qui peut être éligible ?
This study is looking for young people with generalised myasthenia gravis. In the UK and most other countries outside of the USA, children aged 2 to under 18 years old can take part. For those in the USA, participants must be between 12 and under 18 years old. All participants must have a clear diagnosis of generalised myasthenia gravis that has been confirmed by a specific blood test for antibodies.
Your gMG symptoms must be of a certain type and severity, for example, affecting your daily activities with a score of 6 or more on a special scale if you are aged 12 or over. For younger children (2 to under 12 years old), you must have documented weakness in at least one limb, neck, or swallowing muscle. It's also really important that you have had your meningococcal vaccinations or are able to take antibiotics to prevent infection if you haven't been fully vaccinated.
However, some things might mean you can't join the study. For example, if you have a different type of myasthenia gravis (like MUSK positive), or have recently had a serious infection, or have had an operation to remove your thymus gland in the last 6 months, you wouldn't be able to participate. Your study doctor will discuss all these details with you and your family to see if this study is right.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Are you between 2 and under 18 years old (outside USA)?
- Have you been diagnosed with generalised myasthenia gravis (gMG) at your hospital?
- Do you have muscle weakness that affects your daily activities?
- Are your meningococcal vaccinations up to date, or can you take antibiotics?
- Have you *not* had your thymus gland removed in the last 6 months?
- Have you *not* had a serious infection recently that needed strong antibiotics?
En quoi consiste la participation ?
If you decide to take part, you'll receive the study medicine, Zilucoplan, and will have regular check-ups with the study team. These check-ups will involve things like physical examinations, blood tests to see how the medicine is affecting you and to check for side effects, and questions about your symptoms and how you're feeling. You might also have specific tests to measure your muscle strength. The study will involve several visits to the clinic over a period, and you'll be carefully monitored throughout. At each visit, the team will ensure you are comfortable and understand everything that is happening. The full duration of your involvement will be clearly explained by the study staff.
Risques et avantages potentiels
Locations (9)
- Mg0014 50168Code postal vérifiéChicago, États-Unis· Retiré
- Mg0014 50574Code postal vérifiéDenton, United States· Retiré
- Mg0014 40144Code postal vérifiéMilan, Italie· Recrutement
- Mg0014 40774Code postal vérifiéKatowice, Poland· Recrutement
- Mg0014 40218Code postal vérifiéWarsaw, Poland· Actif, mais pas en recrutement
- Mg0014 20104Code postal vérifiéSeoul, South Korea· Retiré
- Mg0014 20220Code postal vérifiéSeoul, South Korea· Recrutement
- Mg0014 40735Code postal vérifiéGlasgow, Royaume-Uni· Recrutement
- Mg0014 40736Code postal vérifiéLondres, Royaume-Uni· Recrutement
Questions fréquentes
What is generalised myasthenia gravis (gMG)?
gMG is a long-term condition that causes muscle weakness and tiredness, affecting muscles that control movement, eyes, speech, and swallowing.
What is Zilucoplan?
Zilucoplan is a new medicine being tested to see if it can help improve symptoms in young people with gMG.
À qui s'adresse cette étude ?
This study is for children and teenagers (aged 2 to under 18, or 12 to under 18 in the USA) who have been diagnosed with generalised myasthenia gravis.
Devrai-je payer pour participer à l'étude ?
No, all study-related treatments and tests are provided at no cost to you or your family.
Puis-je quitter l'étude à tout moment ?
Yes, you or your parent/guardian can decide to leave the study at any point, and it won't affect your regular medical care.
Comment en savoir plus
UCB Prend Soin
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.